Compare DUOL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOL | IONS |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.6B |
| IPO Year | 2021 | 1996 |
| Metric | DUOL | IONS |
|---|---|---|
| Price | $168.76 | $28.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 25 |
| Target Price | ★ $153.93 | $68.48 |
| AVG Volume (30 Days) | 1.4M | ★ 4.2M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 355.85 | 21.71 |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,037,589,000.00 | N/A |
| Revenue This Year | $17.76 | N/A |
| Revenue Next Year | $14.13 | $32.51 |
| P/E Ratio | $79.86 | ★ N/A |
| Revenue Growth | ★ 38.71 | N/A |
| 52 Week Low | $87.89 | $27.25 |
| 52 Week High | $213.37 | $86.74 |
| Indicator | DUOL | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 22.61 |
| Support Level | $97.86 | N/A |
| Resistance Level | N/A | $46.07 |
| Average True Range (ATR) | 9.91 | 2.07 |
| MACD | 2.90 | -1.18 |
| Stochastic Oscillator | 91.96 | 7.56 |
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).